Abbisko IPO: Some Products Show Good Potential but Too Early to Assess Their Success
Abbiskoās development pipeline is comprised of drugs that could become breakthrough therapies in the future, however, these product candidates are...
413 Views
ECM Weekly (26th September 2021) - Hanyu Med, Abbisko, SenseTime, ANE, Nykaa, Prudential HK
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
653 Views
Abbisko IPO: A Promising but Longer Term Prognosis
While both core products are at an early stage of development, promising trials, managementās track record and blue-chip backers suggest that the...
516 Views
Abbisko (åčŖ) Pre-IPO: Strong Team but FGFR Inhibitors Not Convincing Yet
We look at the two main FGFR inhibitor products of Abbisko which is looking to raise up to USD 300m via a Hong Kong listing.
380 Views
InnoCare Pharma Ltd (9969.HK) - Risk of Becoming Mediocre
This article analyzed InnoCare in terms of its core product orelabrutinib, key product candidates in the pipeline, the competitive landscape, the...
408 Views